Tags

Type your tag names separated by a space and hit enter

Resveratrol promotes bone mass in ovariectomized rats and the SIRT1 rs7896005 SNP is associated with bone mass in women during perimenopause and early postmenopause.
Climacteric. 2022 Jun 08 [Online ahead of print]C

Abstract

OBJECTIVE

This study aimed to examine the effects of SIRT1 agonist resveratrol on bone mass in ovariectomized (OVX) rats and the SIRT1 single-nucleotide polymorphism (SNP) rs7896005 on bone mass in women during menopause and early postmenopause.

METHODS

An animal experiment was conducted on rats that were sham-operated (SHAM), OVX or OVX and different administered doses of resveratrol. Serum markers and femur microstructure and staining were assessed. A cross-sectional study was conducted in women undergoing menopause. SIRT1 protein and SIRT1 SNP rs7896005 were evaluated.

RESULTS

OVX rats administered resveratrol, especially high doses, showed lower bone loss than OVX rats. Serum osteoprotegerin (OPG) and femur SIRT1, β-catenin and bone mineral density (BMD) were significantly increased, whereas receptor activator of NF-κB ligand (RANKL) was significantly decreased. Serum SIRT1 levels were significantly lower in women with low bone mass (p < 0.01). Women with the CA genotype of rs7896005 had lower bone mass than those with the CC genotype. The A allele showed a significant negative effect on bone loss risk (odds ratio = 3.48; p = 0.025).

CONCLUSIONS

Resveratrol stimulated SIRT1 expression and Wnt/β-catenin signaling to promote bone mass in rat femurs. Among women in perimenopause and early postmenopause, SIRT1 protected bone mass, and the A allele of SIRT1 rs7896005 was a risk factor for reduced bone mass.

Authors+Show Affiliations

Department of Reproduction Center, Xuzhou Maternity and Child Health Care Hospital, Xuzhou, China.Department of Gynecology, The First People's Hospital of Xiaoshan District, Hangzhou, China.Zhejiang Chinese Medical University, Hangzhou, China.Nanjing Medical University, Nanjing, China.Zhejiang Chinese Medical University, Hangzhou, China.Department of Reproductive Endocrinology Center, Hangzhou Women's Hospital, Hangzhou, China.Department of Reproduction Center, Xuzhou Maternity and Child Health Care Hospital, Xuzhou, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

35674253

Citation

Wang, X, et al. "Resveratrol Promotes Bone Mass in Ovariectomized Rats and the SIRT1 Rs7896005 SNP Is Associated With Bone Mass in Women During Perimenopause and Early Postmenopause." Climacteric : the Journal of the International Menopause Society, 2022, pp. 1-9.
Wang X, Lu C, Chen Y, et al. Resveratrol promotes bone mass in ovariectomized rats and the SIRT1 rs7896005 SNP is associated with bone mass in women during perimenopause and early postmenopause. Climacteric. 2022.
Wang, X., Lu, C., Chen, Y., Wang, Q., Bao, X., Zhang, Z., & Huang, X. (2022). Resveratrol promotes bone mass in ovariectomized rats and the SIRT1 rs7896005 SNP is associated with bone mass in women during perimenopause and early postmenopause. Climacteric : the Journal of the International Menopause Society, 1-9. https://doi.org/10.1080/13697137.2022.2073809
Wang X, et al. Resveratrol Promotes Bone Mass in Ovariectomized Rats and the SIRT1 Rs7896005 SNP Is Associated With Bone Mass in Women During Perimenopause and Early Postmenopause. Climacteric. 2022 Jun 8;1-9. PubMed PMID: 35674253.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resveratrol promotes bone mass in ovariectomized rats and the SIRT1 rs7896005 SNP is associated with bone mass in women during perimenopause and early postmenopause. AU - Wang,X, AU - Lu,C, AU - Chen,Y, AU - Wang,Q, AU - Bao,X, AU - Zhang,Z, AU - Huang,X, Y1 - 2022/06/08/ PY - 2022/6/8/entrez PY - 2022/6/9/pubmed PY - 2022/6/9/medline KW - SIRT1 KW - bone mass KW - menopause KW - resveratrol KW - single-nucleotide polymorphism KW - β-catenin SP - 1 EP - 9 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric N2 - OBJECTIVE: This study aimed to examine the effects of SIRT1 agonist resveratrol on bone mass in ovariectomized (OVX) rats and the SIRT1 single-nucleotide polymorphism (SNP) rs7896005 on bone mass in women during menopause and early postmenopause. METHODS: An animal experiment was conducted on rats that were sham-operated (SHAM), OVX or OVX and different administered doses of resveratrol. Serum markers and femur microstructure and staining were assessed. A cross-sectional study was conducted in women undergoing menopause. SIRT1 protein and SIRT1 SNP rs7896005 were evaluated. RESULTS: OVX rats administered resveratrol, especially high doses, showed lower bone loss than OVX rats. Serum osteoprotegerin (OPG) and femur SIRT1, β-catenin and bone mineral density (BMD) were significantly increased, whereas receptor activator of NF-κB ligand (RANKL) was significantly decreased. Serum SIRT1 levels were significantly lower in women with low bone mass (p < 0.01). Women with the CA genotype of rs7896005 had lower bone mass than those with the CC genotype. The A allele showed a significant negative effect on bone loss risk (odds ratio = 3.48; p = 0.025). CONCLUSIONS: Resveratrol stimulated SIRT1 expression and Wnt/β-catenin signaling to promote bone mass in rat femurs. Among women in perimenopause and early postmenopause, SIRT1 protected bone mass, and the A allele of SIRT1 rs7896005 was a risk factor for reduced bone mass. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/35674253/Resveratrol_promotes_bone_mass_in_ovariectomized_rats_and_the_SIRT1_rs7896005_SNP_is_associated_with_bone_mass_in_women_during_perimenopause_and_early_postmenopause. L2 - https://www.tandfonline.com/doi/full/10.1080/13697137.2022.2073809 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.